Broadly neutralizing antibodies targeting the HIV-1 envelope V2 apex confer protection against a clade C SHIV challenge

Science Translational Medicine

Volumn 9, Issue 406, 2017, Pages

  Julg, Boris ^a,b   Tartaglia, Lawrence J ^b   Keele, Brandon F ^c   Wagh, Kshitij ^d   Pegu, Amarendra ^e   Sok, Devin ^f   Abbink, Peter ^b   Schmidt, Stephen D ^e   Wang, Keyun ^e   Chen, Xuejun ^e   Joyce, M Gordon ^e   Georgiev, Ivelin S ^e   Choe, Misook ^e   Kwong, Peter D ^e   Doria Rose, Nicole A ^e   Le, Khoa ^f   Louder, Mark K ^e   Bailer, Robert T ^e   Moore, Penny L ^g,h   Korber, Bette ^d   Seaman, Michael S ^b   Abdool Karim, Salim S ^h,i   Morris, Lynn ^g,h   Koup, Richard A ^e   Mascola, John R ^e   Burton, Dennis R ^a,f   Barouch, Dan H ^a,b   more..

^a HARVARD UNIVERSITY   (United States)

^b BETH ISRAEL DEACONESS MEDICAL CENTER   (United States)

^c FREDERICK NATIONAL LABORATORY FOR CANCER RESEARCH   (United States)

^d LOS ALAMOS NATIONAL LABORATORY   (United States)

^e NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

^f SCRIPPS RESEARCH INSTITUTE   (United States)

^g UNIVERSITY OF THE WITWATERSRAND   (South Africa)

^h UNIVERSITY OF KWAZULU NATAL   (South Africa)

ⁱ Och Spine at New York Presbyterian Hospitals   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CAP256-VRC26.25; CROSS REACTING ANTIBODY; HUMAN IMMUNODEFICIENCY VIRUS ANTIGEN; NEUTRALIZING ANTIBODY; PG9; PGDM1400; UNCLASSIFIED DRUG; V2 SPECIFIC NEUTRALIZING ANTIBODY; GLYCOPROTEIN GP 120;

ADULT; ANIMAL EXPERIMENT; ANIMAL TISSUE; ANTIBODY BLOOD LEVEL; ANTIBODY SPECIFICITY; ANTIGEN STRUCTURE; ARTICLE; CLADISTICS; CONTROLLED STUDY; DRUG TARGETING; FEMALE; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; MALE; NONHUMAN; PASSIVE IMMUNIZATION; PRIMATE; PRIORITY JOURNAL; RHESUS MONKEY; VIRUS ENVELOPE; VIRUS NEUTRALIZATION; AMINO ACID SEQUENCE; ANIMAL; BLOOD; CD4+ T LYMPHOCYTE; CHEMISTRY; IMMUNOLOGY; METABOLISM; SEQUENCE ALIGNMENT; SERODIAGNOSIS; SIMIAN ACQUIRED IMMUNODEFICIENCY SYNDROME; SIMIAN IMMUNODEFICIENCY VIRUS; VIROLOGY; VIRUS LOAD;

AMINO ACID SEQUENCE; ANIMALS; ANTIBODIES, NEUTRALIZING; CD4-POSITIVE T-LYMPHOCYTES; FEMALE; HIV ENVELOPE PROTEIN GP120; HIV-1; MACACA MULATTA; MALE; NEUTRALIZATION TESTS; SEQUENCE ALIGNMENT; SIMIAN ACQUIRED IMMUNODEFICIENCY SYNDROME; SIMIAN IMMUNODEFICIENCY VIRUS; VIRAL LOAD;

EID: 85028951664     PISSN: 19466234     EISSN: 19466242     Source Type: Journal    
DOI: 10.1126/scitranslmed.aal1321     Document Type: Article

References (49)

1. K. E. Stephenson, H. T. D’Couto, D. H. Barouch, New concepts in HIV-1 vaccine development. Curr. Opin. Immunol. 41, 39–46 (2016).
2. N. A. Doria-Rose, R. M. Klein, M. G. Daniels, S. O’Dell, M. Nason, A. Lapedes, T. Bhattacharya, S. A. Migueles, R. T. Wyatt, B. T. Korber, J. R. Mascola, M. Connors, Breadth of human immunodeficiency virus-specific neutralizing activity in sera: Clustering analysis and association with clinical variables. J. Virol. 84, 1631–1636 (2010).
3. Z. Euler, M. J. van Gils, E. M. Bunnik, P. Phung, B. Schweighardt, T. Wrin, H. Schuitemaker, Cross-reactive neutralizing humoral immunity does not protect from HIV type 1 disease progression. J. Infect. Dis. 201, 1045–1053 (2010).
4. P. Hraber, M. S. Seaman, R. T. Bailer, J. R. Mascola, D. C. Montefiori, B. T. Korber, Prevalence of broadly neutralizing antibody responses during chronic HIV-1 infection. AIDS 28, 163–169 (2014).
5. L. M. Walker, M. Huber, K. J. Doores, E. Falkowska, R. Pejchal, J.-P. Julien, S.-K. Wang, A. Ramos, P.-Y. Chan-Hui, M. Moyle, J. L. Mitcham, P. W. Hammond, O. A. Olsen, P. Phung, S. Fling, C.-H. Wong, S. Phogat, T. Wrin, M. D. Simek; Protocol G. Principal Investigators, W. C. Koff, I. A. Wilson, D. R. Burton, P. Poignard, Broad neutralization coverage of HIV by multiple highly potent antibodies. Nature 477, 466–470 (2011).
6. D. R. Burton, J. R. Mascola, Antibody responses to envelope glycoproteins in HIV-1 infection. Nat. Immunol. 16, 571–576 (2015).
7. D. R. Burton, L. Hangartner, Broadly neutralizing antibodies to HIV and their role in vaccine design. Annu. Rev. Immunol. 34, 635–659 (2016).
8. D. Corti, A. Lanzavecchia, Broadly neutralizing antiviral antibodies. Annu. Rev. Immunol. 31, 705–742 (2013).
9. B. Moldt, E. G. Rakasz, N. Schultz, P.-Y. Chan-Hui, K. Swiderek, K. L. Weisgrau, S. M. Piaskowski, Z. Bergman, D. I. Watkins, P. Poignard, D. R. Burton, Highly potent HIV-specific antibody neutralization in vitro translates into effective protection against mucosal SHIV challenge in vivo. Proc. Natl. Acad. Sci. U.S.A. 109, 18921–18925 (2012).
10. M. Shingai, O. K. Donau, R. J. Plishka, A. Buckler-White, J. R. Mascola, G. J. Nabel, M. C. Nason, D. Montefiori, B. Moldt, P. Poignard, R. Diskin, P. J. Bjorkman, M. A. Eckhaus, F. Klein, H. Mouquet, J. C. Cetrulo Lorenzi, A. Gazumyan, D. R. Burton, M. C. Nussenzweig, M. A. Martin, Y. Nishimura, Passive transfer of modest titers of potent and broadly neutralizing anti-HIV monoclonal antibodies block SHIV infection in macaques. J. Exp. Med. 211, 2061–2074 (2014).
11. A. Pegu, Z.-y. Yang, J. C. Boyington, L. Wu, S.-Y. Ko, S. D. Schmidt, K. McKee, W.-P. Kong, W. Shi, X. Chen, J.-P. Todd, N. L. Letvin, J. Huang, M. C. Nason, J. A. Hoxie, P. D. Kwong, M. Connors, S. S. Rao, J. R. Mascola, G. J. Nabel, Neutralizing antibodies to HIV-1 envelope protect more effectively in vivo than those to the CD4 receptor. Sci. Transl. Med. 6, 243ra288 (2014).
12. R. Gautam, Y. Nishimura, A. Pegu, M. C. Nason, F. Klein, A. Gazumyan, J. Golijanin, A. Buckler-White, R. Sadjadpour, K. Wang, Z. Mankoff, S. D. Schmidt, J. D. Lifson, J. R. Mascola, M. C. Nussenzweig, M. A. Martin, A single injection of anti-HIV-1 antibodies protects against repeated SHIV challenges. Nature 533, 105–109 (2016).
13. L. M. Walker, M. D. Simek, F. Priddy, J. S. Gach, D. Wagner, M. B. Zwick, S. K. Phogat, P. Poignard, D. R. Burton, A limited number of antibody specificities mediate broad and potent serum neutralization in selected HIV-1 infected individuals. PLOS Pathog. 6, e1001028 (2010).
14. I. S. Georgiev, N. A. Doria-Rose, T. Zhou, Y. D. Kwon, R. P. Staupe, S. Moquin, G.-Y. Chuang, M. K. Louder, S. D. Schmidt, H. R. Altae-Tran, R. T. Bailer, K. McKee, M. Nason, S. O’Dell, G. Ofek, M. Pancera, S. Srivatsan, L. Shapiro, M. Connors, S. A. Migueles, L. Morris, Y. Nishimura, M. A. Martin, J. R. Mascola, P. D. Kwong, Delineating antibody recognition in polyclonal sera from patterns of HIV-1 isolate neutralization. Science 340, 751–756 (2013).
15. E. Landais, X. Huang, C. Havenar-Daughton, B. Murrell, M. A. Price, L. Wickramasinghe, A. Ramos, C. B. Bian, M. Simek, S. Allen, E. Karita, W. Kilembe, S. Lakhi, M. Inambao, A. Kamali, E. J. Sanders, O. Anzala, V. Edward, L.-G. Bekker, J. Tang, J. Gilmour, S. L. Kosakovsky-Pond, P. Phung, T. Wrin, S. Crotty, A. Godzik, P. Poignard, Broadly neutralizing antibody responses in a large longitudinal sub-saharan HIV primary infection cohort. PLOS Pathog. 12, e1005369 (2016).
16. R. Pan, M. K. Gorny, S. Zolla-Pazner, X.-P. Kong, The V1V2 region of HIV-1 gp120 forms a five-stranded beta barrel. J. Virol. 89, 8003–8010 (2015).
17. B. F. Haynes, P. B. Gilbert, M. J. McElrath, S. Zolla-Pazner, G. D. Tomaras, S. M. Alam, D. T. Evans, D. C. Montefiori, C. Karnasuta, R. Sutthent, H.-X. Liao, A. L. DeVico, G. K. Lewis, C. Williams, A. Pinter, Y. Fong, H. Janes, A. DeCamp, Y. Huang, M. Rao, E. Billings, N. Karasavvas, M. L. Robb, V. Ngauy, M. S. de Souza, R. Paris, G. Ferrari, R. T. Bailer, K. A. Soderberg, C. Andrews, P. W. Berman, N. Frahm, S. C. De Rosa, M. D. Alpert, N. L. Yates, X. Shen, R. A. Koup, P. Pitisuttithum, J. Kaewkungwal, S. Nitayaphan, S. Rerks-Ngarm, N. L. Michael, J. H. Kim, Immune-correlates analysis of an HIV-1 vaccine efficacy trial. N. Engl. J. Med. 366, 1275–1286 (2012).
18. L. M. Walker, S. K. Phogat, P.-Y. Chan-Hui, D. Wagner, P. Phung, J. L. Goss, T. Wrin, M. D. Simek, S. Fling, J. L. Mitcham, J. K. Lehrman, F. H. Priddy, O. A. Olsen, S. M. Frey, P. W. Hammond; Protocol G Principal Investigators, S. Kaminsky, T. Zamb, M. Moyle, W. C. Koff, P. Poignard, D. R. Burton, Broad and potent neutralizing antibodies from an African donor reveal a new HIV-1 vaccine target. Science 326, 285–289 (2009).
19. M. Bonsignori, K.-K. Hwang, X. Chen, C.-Y. Tsao, L. Morris, E. Gray, D. J. Marshall, J. A. Crump, S. H. Kapiga, N. E. Sam, F. Sinangil, M. Pancera, Y. Yongping, B. Zhang, J. Zhu, P. D. Kwong, S. O’Dell, J. R. Mascola, L. Wu, G. J. Nabel, S. Phogat, M. S. Seaman, J. F. Whitesides, M. A. Moody, G. Kelsoe, X. Yang, J. Sodroski, G. M. Shaw, D. C. Montefiori, T. B. Kepler, G. D. Tomaras, S. M. Alam, H.-X. Liao, B. F. Haynes, Analysis of a clonal lineage of HIV-1 envelope V2/V3 conformational epitope-specific broadly neutralizing antibodies and their inferred unmutated common ancestors. J. Virol. 85, 9998–10009 (2011).
20. N. A. Doria-Rose, C. A. Schramm, J. Gorman, P. L. Moore, J. N. Bhiman, B. J. DeKosky, M. J. Ernandes, I. S. Georgiev, H. J. Kim, M. Pancera, R. P. Staupe, H. R. Altae-Tran, R. T. Bailer, E. T. Crooks, A. Cupo, A. Druz, N. J. Garrett, K. H. Hoi, R. Kong, M. K. Louder, N. S. Longo, K. McKee, M. Nonyane, S. O’Dell, R. S. Roark, R. S. Rudicell, S. D. Schmidt, D. J. Sheward, C. Soto, C. K. Wibmer, Y. Yang, Z. Zhang; NISC Comparative Sequencing, J. C. Mullikin, J. M. Binley, R. W. Sanders, I. A. Wilson, J. P. Moore, A. B. Ward, G. Georgiou, C. Williamson, S. S. Abdool Karim, L. Morris, P. D. Kwong, L. Shapiro, J. R. Mascola, Developmental pathway for potent V1V2-directed HIV-neutralizing antibodies. Nature 509, 55–62 (2014).
21. N. A. Doria-Rose, J. N. Bhiman, R. S. Roark, C. A. Schramm, J. Gorman, G.-Y. Chuang, M. Pancera, E. M. Cale, M. J. Ernandes, M. K. Louder, M. Asokan, R. T. Bailer, A. Druz, I. R. Fraschilla, N. J. Garrett, M. Jarosinski, R. M. Lynch, K. McKee, S. O’Dell, A. Pegu, S. D. Schmidt, R. P. Staupe, M. S. Sutton, K. Wang, C. K. Wibmer, B. F. Haynes, S. Abdool-Karim, L. Shapiro, P. D. Kwong, P. L. Moore, L. Morris, J. R. Mascola, New member of the V1V2-directed CAP256-VRC26 lineage that shows increased breadth and exceptional potency. J. Virol. 90, 76–91 (2016).
22. D. Sok, M. J. van Gils, M. Pauthner, J.-P. Julien, K. L. Saye-Francisco, J. Hsueh, B. Briney, J. H. Lee, K. M. Le, P. S. Lee, Y. Hua, M. S. Seaman, J. P. Moore, A. B. Ward, I. A. Wilson, R. W. Sanders, D. R. Burton, Recombinant HIV envelope trimer selects for quaternary-dependent antibodies targeting the trimer apex. Proc. Natl. Acad. Sci. U.S.A. 111, 17624–17629 (2014).
23. K. Wagh, T. Bhattacharya, C. Williamson, A. Robles, M. Bayne, J. Garrity, M. Rist, C. Rademeyer, H. Yoon, A. Lapedes, H. Gao, K. Greene, M. K. Louder, R. Kong, S. A. Karim, D. R. Burton, D. H. Barouch, M. C. Nussenzweig, J. R. Mascola, L. Morris, D. C. Montefiori, B. Korber, M. S. Seaman, Optimal combinations of broadly neutralizing antibodies for prevention and treatment of HIV-1 clade C infection. PLOS Pathog. 12, e1005520 (2016).
24. G. E. Gray, M. Allen, Z. Moodie, G. Churchyard, L.-G. Bekker, M. Nchabeleng, K. Mlisana, B. Metch, G. de Bruyn, M. H. Latka, S. Roux, M. Mathebula, N. Naicker, C. Ducar, D. K. Carter, A. Puren, N. Eaton, M. J. McElrath, M. Robertson, L. Corey, J. G. Kublin; HVTN 503/Phambili study team, Safety and efficacy of the HVTN 503/Phambili study of a clade-B-based HIV-1 vaccine in South Africa: A double-blind, randomised, placebo-controlled test-of-concept phase 2b study. Lancet Infect. Dis. 11, 507–515 (2011).
25. J. M. Harouse, A. Gettie, T. Eshetu, R. C. H. Tan, R. Bohm, J. Blanchard, G. Baskin, C. Cheng-Mayer, Mucosal transmission and induction of simian AIDS by CCR5-specific simian/human immunodeficiency virus SHIVSF162P3. J. Virol. 75, 1990–1995 (2001).
26. R. Gautam, Y. Nishimura, W. R. Lee, O. Donau, A. Buckler-White, M. Shingai, R. Sadjadpour, S. D. Schmidt, C. C. LaBranche, B. F. Keele, D. Montefiori, J. R. Mascola, M. A. Martin, Pathogenicity and mucosal transmissibility of the R5-tropic simian/human immunodeficiency virus SHIVAD8 in rhesus macaques: Implications for use in vaccine studies. J. Virol. 86, 8516–8526 (2012).
27. S.-Y. Ko, A. Pegu, R. S. Rudicell, Z.-y. Yang, M. G. Joyce, X. Chen, K. Wang, S. Bao, T. D. Kraemer, T. Rath, M. Zeng, S. D. Schmidt, J.-P. Todd, S. R. Penzak, K. O. Saunders, M. C. Nason, A. T. Haase, S. S. Rao, R. S. Blumberg, J. R. Mascola, G. J. Nabel, Enhanced neonatal Fc receptor function improves protection against primate SHIV infection. Nature 514, 642–645 (2014).
28. P. L. Moore, D. Sheward, M. Nonyane, N. Ranchobe, T. Hermanus, E. S. Gray, S. S. Abdool Karim, C. Williamson, L. Morris, Multiple pathways of escape from HIV broadly cross-neutralizing V2-dependent antibodies. J. Virol. 87, 4882–4894 (2013).
29. J. N. Bhiman, C. Anthony, N. A. Doria-Rose, O. Karimanzira, C. A. Schramm, T. Khoza, D. Kitchin, G. Botha, J. Gorman, N. J. Garrett, S. S. Abdool Karim, L. Shapiro, C. Williamson, P. D. Kwong, J. R. Mascola, L. Morris, P. L. Moore, Viral variants that initiate and drive maturation of V1V2-directed HIV-1 broadly neutralizing antibodies. Nat. Med. 21, 1332–1336 (2015).
30. P. L. Moore, E. S. Gray, D. Sheward, M. Madiga, N. Ranchobe, Z. Lai, W. J. Honnen, M. Nonyane, N. Tumba, T. Hermanus, S. Sibeko, K. Mlisana, S. S. Abdool Karim, C. Williamson, A. Pinter, L. Morris; CAPRISA 002 Study, Potent and broad neutralization of HIV-1 subtype C by plasma antibodies targeting a quaternary epitope including residues in the V2 loop. J. Virol. 85, 3128–3141 (2011).
31. A. Pegu, A. J. Hessell, J. R. Mascola, N. L. Haigwood, Use of broadly neutralizing antibodies for HIV-1 prevention. Immunol. Rev. 275, 296–312 (2017).
32. J. E. Ledgerwood, E. E. Coates, G. Yamshchikov, J. G. Saunders, L. Holman, M. E. Enama, A. DeZure, R. M. Lynch, I. Gordon, S. Plummer, C. S. Hendel, A. Pegu, M. Conan-Cibotti, S. Sitar, R. T. Bailer, S. Narpala, A. McDermott, M. Louder, S. O’Dell, S. Mohan, J. P. Pandey, R. M. Schwartz, Z. Hu, R. A. Koup, E. Capparelli, J. R. Mascola, B. S. Graham; VRC 602 Study Team, Safety, pharmacokinetics and neutralization of the broadly neutralizing HIV-1 human monoclonal antibody VRC01 in healthy adults. Clin. Exp. Immunol. 182, 289–301 (2015).
33. L. E. McCoy, E. Falkowska, K. J. Doores, K. Le, D. Sok, M. J. van Gils, Z. Euler, J. A. Burger, M. S. Seaman, R. W. Sanders, H. Schuitemaker, P. Poignard, T. Wrin, D. R. Burton, Incomplete neutralization and deviation from sigmoidal neutralization curves for HIV broadly neutralizing monoclonal antibodies. PLOS Pathog. 11, e1005110 (2015).
34. D. H. Barouch, J. B. Whitney, B. Moldt, F. Klein, T. Y. Oliveira, J. Liu, K. E. Stephenson, H.-W. Chang, K. Shekhar, S. Gupta, J. P. Nkolola, M. S. Seaman, K. M. Smith, E. N. Borducchi, C. Cabral, J. Y. Smith, S. Blackmore, S. Sanisetty, J. R. Perry, M. Beck, M. G. Lewis, W. Rinaldi, A. K. Chakraborty, P. Poignard, M. C. Nussenzweig, D. R. Burton, Therapeutic efficacy of potent neutralizing HIV-1-specific monoclonal antibodies in SHIV-infected rhesus monkeys. Nature 503, 224–228 (2013).
35. K. J. Bar, M. C. Sneller, L. J. Harrison, J. S. Justement, E. T. Overton, M. E. Petrone, D. B. Salantes, C. A. Seamon, B. Scheinfeld, R. W. Kwan, G. H. Learn, M. A. Proschan, E. F. Kreider, J. Blazkova, M. Bardsley, E. W. Refsland, M. Messer, K. E. Clarridge, N. B. Tustin, P. J. Madden, K. Oden, S. J. O’Dell, B. Jarocki, A. R. Shiakolas, R. L. Tressler, N. A. Doria-Rose, R. T. Bailer, J. E. Ledgerwood, E. V. Capparelli, R. M. Lynch, B. S. Graham, S. Moir, R. A. Koup, J. R. Mascola, J. A. Hoxie, A. S. Fauci, P. Tebas, T.-W. Chun, Effect of HIV antibody VRC01 on viral rebound after treatment interruption. N. Engl. J. Med. 375, 2037–2050 (2016).
36. J. F. Scheid, J. A. Horwitz, Y. Bar-On, E. F. Kreider, C.-L. Lu, J. C. C. Lorenzi, A. Feldmann, M. Braunschweig, L. Nogueira, T. Oliveira, I. Shimeliovich, R. Patel, L. Burke, Y. Z. Cohen, S. Hadrigan, A. Settler, M. Witmer-Pack, A. P. West Jr., B. Juelg, T. Keler, T. Hawthorne, B. Zingman, R. M. Gulick, N. Pfeifer, G. H. Learn, M. S. Seaman, P. J. Bjorkman, F. Klein, S. J. Schlesinger, B. D. Walker, B. H. Hahn, M. C. Nussenzweig, M. Caskey, HIV-1 antibody 3BNC117 suppresses viral rebound in humans during treatment interruption. Nature 535, 556–560 (2016).
37. Y. Mao, L. Wang, C. Gu, A. Herschhorn, S.-H. Xiang, H. Haim, X. Yang, J. Sodroski, Subunit organization of the membrane-bound HIV-1 envelope glycoprotein trimer. Nat. Struct. Mol. Biol. 19, 893–899 (2012).
38. P. Rusert, A. Krarup, C. Magnus, O. F. Brandenberg, J. Weber, A. K. Ehlert, R. R. Regoes, H. F. Günthard, A. Trkola, Interaction of the gp120 V1V2 loop with a neighboring gp120 unit shields the HIV envelope trimer against cross-neutralizing antibodies. J. Exp. Med. 208, 1419–1433 (2011).
39. P. W. H. I. Parren, P. A. Marx, A. J. Hessell, A. Luckay, J. Harouse, C. Cheng-Mayer, J. P. Moore, D. R. Burton, Antibody protects macaques against vaginal challenge with a pathogenic R5 simian/human immunodeficiency virus at serum levels giving complete neutralization in vitro. J. Virol. 75, 8340–8347 (2001).
40. H.-W. Chang, L. J. Tartaglia, J. B. Whitney, S.-Y. Lim, S. Sanisetty, C. L. Lavine, M. S. Seaman, C. Rademeyer, C. Williamson, K. Ellingson-Strouss, L. Stamatatos, J. Kublin, D. H. Barouch, Generation and evaluation of clade C simian-human immunodeficiency virus challenge stocks. J. Virol. 89, 1965–1974 (2015).
41. L. J. Tartaglia, H.-W. Chang, B. C. Lee, P. Abbink, D. Ng’ang’a, M. Boyd, C. L. Lavine, S.-Y. Lim, S. Sanisetty, J. B. Whitney, M. S. Seaman, M. Rolland, S. Tovanabutra, J. Ananworanich, M. L. Robb, J. H. Kim, N. L. Michael, D. H. Barouch, Production of mucosally transmissible SHIV challenge stocks from HIV-1 circulating recombinant form 01_AE env sequences. PLOS Pathog. 12, e1005431 (2016).
42. J.-P. Julien, A. Cupo, D. Sok, R. L. Stanfield, D. Lyumkis, M. C. Deller, P.-J. Klasse, D. R. Burton, R. W. Sanders, J. P. Moore, A. B. Ward, I. A. Wilson, Crystal structure of a soluble cleaved HIV-1 envelope trimer. Science 342, 1477–1483 (2013).
43. R. W. Sanders, R. Derking, A. Cupo, J.-P. Julien, A. Yasmeen, N. de Val, H. J. Kim, C. Blattner, A. T. de la Peña, J. Korzun, M. Golabek, K. de los Reyes, T. J. Ketas, M. J. van Gils, C. R. King, I. A. Wilson, A. B. Ward, P. J. Klasse, J. P. Moore, A next-generation cleaved, soluble HIV-1 Env trimer, BG505 SOSIP.664 gp140, expresses multiple epitopes for broadly neutralizing but not non-neutralizing antibodies. PLOS Pathog. 9, e1003618 (2013).
44. H. Shang, X. Han, X. Shi, T. Zuo, M. Goldin, D. Chen, B. Han, W. Sun, H. Wu, X. Wang, L. Zhang, Genetic and neutralization sensitivity of diverse HIV-1 env clones from chronically infected patients in China. J. Biol. Chem. 286, 14531–14541 (2011).
45. M. Pancera, T. Zhou, A. Druz, I. S. Georgiev, C. Soto, J. Gorman, J. Huang, P. Acharya, G.-Y. Chuang, G. Ofek, G. B. E. Stewart-Jones, J. Stuckey, R. T. Bailer, M. G. Joyce, M. K. Louder, N. Tumba, Y. Yang, B. Zhang, M. S. Cohen, B. F. Haynes, J. R. Mascola, L. Morris, J. B. Munro, S. C. Blanchard, W. Mothes, M. Connors, P. D. Kwong, Structure and immune recognition of trimeric pre-fusion HIV-1 Env. Nature 514, 455–461 (2014).
46. J. P. Nkolola, H. Peng, E. C. Settembre, M. Freeman, L. E. Grandpre, C. Devoy, D. M. Lynch, A. La Porte, N. L. Simmons, R. Bradley, D. C. Montefiori, M. S. Seaman, B. Chen, D. H. Barouch, Breadth of neutralizing antibodies elicited by stable, homogeneous clade A and clade C HIV-1 gp140 envelope trimers in guinea pigs. J. Virol. 84, 3270–3279 (2010).
47. M. Li, F. Gao, J. R. Mascola, L. Stamatatos, V. R. Polonis, M. Koutsoukos, G. Voss, P. Goepfert, P. Gilbert, K. M. Greene, M. Bilska, D. L. Kothe, J. F. Salazar-Gonzalez, X. Wei, J. M. Decker, B. H. Hahn, D. C. Montefiori, Human immunodeficiency virus type 1 env clones from acute and early subtype B infections for standardized assessments of vaccine-elicited neutralizing antibodies. J. Virol. 79, 10108–10125 (2005).
48. D. C. Montefiori, Measuring HIV neutralization in a luciferase reporter gene assay. Methods Mol. Biol. 485, 395–405 (2009).
49. B. F. Keele, E. E. Giorgi, J. F. Salazar-Gonzalez, J. M. Decker, K. T. Pham, M. G. Salazar, C. Sun, T. Grayson, S. Wang, H. Li, X. Wei, C. Jiang, J. L. Kirchherr, F. Gao, J. A. Anderson, L.-H. Ping, R. Swanstrom, G. D. Tomaras, W. A. Blattner, P. A. Goepfert, J. M. Kilby, M. S. Saag, E. L. Delwart, M. P. Busch, M. S. Cohen, D. C. Montefiori, B. F. Haynes, B. Gaschen, G. S. Athreya, H. Y. Lee, N. Wood, C. Seoighe, A. S. Perelson, T. Bhattacharya, B. T. Korber, B. H. Hahn, G. M. Shaw, Identification and characterization of transmitted and early founder virus envelopes in primary HIV-1 infection. Proc. Natl. Acad. Sci. U.S.A. 105, 7552–7557 (2008).